Biodexa Pharmaceuticals
BDRX
4 hedge funds and large institutions have $169K invested in Biodexa Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
300% more funds holding
Funds holding: 1 → 4 (+3)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
187% more capital invested
Capital invested by funds: $58.9K → $169K (+$110K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$153K |
| 2 |
Renaissance Technologies
New York
|
+$38.2K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$57.2K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$254 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boothbay Fund Management
New York
| $120K | +$153K | +36 | New |
|
|
2
Renaissance Technologies
New York
| $31K | +$38.2K | +9 | New |
|
|
3
Bank of America
Charlotte,
North Carolina
| $14K | +$17K | +4 | New |
|
|
GI
4
GAMMA Investing
Foster City,
California
| $1.67K | +$4.25K | +1 | New |
|
5
UBS Group
Zurich,
Switzerland
| $1.61K | – | – | – |
|
6
RhumbLine Advisers
Boston,
Massachusetts
| $1.33K | – | – | – |
|
7
Morgan Stanley
New York
| $86 | – | – | – |
|
|
8
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$57.2K | -9 | Closed |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$254 | – | – |
|
BDRX Hedge Fund Activity: Q4 2023 in Review
4 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q4 2023, worth a combined $169K — up 187% from $58.9K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BDRX positions and 1 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $153K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $57.2K sold.
- 4 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q4 2023, up from 1 in Q3 2023.
- Funds reported $169K of Biodexa Pharmaceuticals stock for Q4 2023, up 187% quarter-over-quarter.
- 4 funds opened new Biodexa Pharmaceuticals positions in Q4 2023 and 1 closed out, a net change of +3 holders.
- The largest Biodexa Pharmaceuticals buyer in Q4 2023 was Boothbay Fund Management, an estimated $153K added.
- The largest Biodexa Pharmaceuticals seller in Q4 2023 was Susquehanna International Group, an estimated $57.2K sold.
Based on aggregated 13F filings for Q4 2023.